ezetimibe has been researched along with Inflammation in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (15.22) | 29.6817 |
| 2010's | 30 (65.22) | 24.3611 |
| 2020's | 9 (19.57) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, P; Wang, Y; Xia, Y; Yuan, X; Zhong, Y; Zhu, L | 1 |
| Han, J; Hu, T; Luo, J; Shen, X; Weng, Q; Zhang, Y | 1 |
| Ju, SH; Ku, BJ | 1 |
| Drexel, H; Klement, M; Saely, CH | 1 |
| Deng, J; Li, H; Rong, W; Xiao, S; Yang, H; Yuan, B; Zhang, C; Zhu, J | 1 |
| Genkel, VV; Shaposhnik, II | 1 |
| Chen, SP; Li, X; Matei, N; Mo, J; Pang, JW; Tang, JP; Wang, WN; Yan, M; Yu, J; Zhang, JH | 1 |
| Agrawal, H; Albert, MA; Auyoung, M; Choy, HK; Liu, J | 1 |
| Arrese, M; Bizama, C; Espinoza, JA; Ferreccio, C; García, P; Gómez, N; González, X; Guevara, F; Kalergis, AM; Lobos-González, L; Miquel, JF; Muñoz-Durango, N; Roa, JC; Rosa, L; Saavedra, N; Villegas, J; Wichmann, IA | 1 |
| Lekuona, I; Pintó, X | 1 |
| Bae, SH; Cha, BS; Han, DH; Kang, ES; Kim, B; Kim, G; Kim, I; Kim, KH; Kim, SH; Lee, BW; Lee, M; Lee, MS; Lee, YH; Song, YM; Wang, HJ; Yoo, JE | 1 |
| Bernik, MMS; Cerda, A; Dorea, EL; Fajardo, CM; Guimarães, ES; Gusukuma, MC; Hirata, MH; Hirata, RDC; Pinto, GA | 1 |
| Chang, Y; Chen, YG; Ji, XP; Li, CB; Li, XX; Liu, BS; Xu, F; Zhang, C; Zhao, L | 1 |
| Dong, Q; Gao, Y; Guo, YL; Li, JJ; Liu, G; Sun, D; Sun, J; Wu, NQ; Xu, RX; Zhao, X; Zhu, CG | 1 |
| Chen, HJ; Cho, CL; Liang, CL; Liliang, PC; Lu, K; Tsai, YD; Wang, HK; Wang, KW | 1 |
| Bode, C; Clemens, A; Hehn, P; Hilgendorf, I; Kaier, K; Manhart, L; Merz, J; Peikert, A; Schäfer, I; Sheng, X; Stachon, P; von Zur Mühlen, C; Willecke, F; Wolf, D; Zehender, M; Zirlik, A | 1 |
| Aguirre, AC; Amaral, JB; Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN; Santana, JM | 1 |
| Lappegård, KT; Pop, G; Pop-Purceleanu, M; Sexton, J; Tendolkar, I; van Heerde, W | 1 |
| Shoji, T | 1 |
| Barbosa, CP; Bersani-Amado, CA; Cuman, RK; da Silva, LG; Grespan, R; Hernandes, L; Ritter, AM | 1 |
| Aukrust, P; Halvorsen, B; Holven, KB; Langslet, G; Lindvig, HW; Narverud, I; Nenseter, MS; Ose, L; Retterstøl, K; Ulven, SM | 1 |
| Almquist, T; Hjemdahl, P; Jacobson, SH; Mobarrez, F; Näsman, P | 1 |
| Brudi, P; Catapano, AL; Farnier, M; Foody, JM; Tershakovec, AM; Tomassini, JE; Toth, PP | 1 |
| Carru, C; Mangoni, AA; Sanna, M; Satta, AE; Sotgia, S; Zinellu, A | 1 |
| Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A | 1 |
| Chung, RT; Corey, KE; Giugliano, R; Simon, TG | 1 |
| Ames, FQ; Barbosa, CP; Bersani-Amado, CA; Bracht, L; de Souza Silva-Comar, FM; Tronco, RP | 1 |
| Aragoncillo, P; Fernández-Cruz, A; Gómez-Garre, D; González-Rubio, ML; Granados, R; Muñoz-Pacheco, P | 1 |
| Tomkin, GH | 1 |
| Elisaf, M; Kalogirou, M; Tsimihodimos, V | 1 |
| Chambers, JB; Viljoen, A; Wierzbicki, AS | 1 |
| Flameng, W; Herijgers, P; Hermans, H; Herregods, MC; Holvoet, P; Meuris, B; Verbeken, E | 1 |
| Ahmed, MH; Byrne, CD | 1 |
| Bangit, JR; Batsell, RR; Miraskar, RA; Reddy, KJ; Singh, M; Zaheer, MS | 1 |
| Krysiak, R; Okopien, B; Zmuda, W | 1 |
| Morinaga, Y; Nakazato, M; Shiiya, T; Tamaki, N; Ueno, H | 1 |
| Asano, R; Hagiwara, N; Seki, A; Sumiyoshi, T; Tobaru, T | 1 |
| Arai, H; Matsubara, T; Minami, M; Murayama, T; Tamura, Y; Yokode, M | 1 |
| Fujisawa, K; Kuwashiro, S; Matsumoto, T; Nishina, H; Oishi, T; Sakaida, I; Terai, S | 1 |
| Chait, A; Ding, Y; Goodspeed, L; Han, CY; Kim, J; O'Brien, KD; Subramanian, S; Teresa, AS; Umemoto, T; Wang, S | 1 |
| Iino, K; Ishida, M; Ito, H; Kosaka, T; Koyama, T; Nobori, K; Oguma, Y; Terata, Y; Watanabe, H; Yamazaki, D | 1 |
| Sármán, B | 1 |
| Dagli, N; Karaca, I; Yavuzkir, M | 1 |
| Booth, AD; Brown, J; Hall, FC; Mäki-Petäjä, KM; McEniery, CM; Wallace, SM; Wilkinson, IB | 1 |
| Stein, EA | 1 |
| Bauersachs, J; Ertl, G; Hu, K; Huang, PL; Kuhlencordt, PJ; Padmapriya, P; Rützel, S; Schäfer, A; Schödel, J | 1 |
10 review(s) available for ezetimibe and Inflammation
| Article | Year |
|---|---|
Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Tumor Necrosis Factor-alpha | 2023 |
Coronary Artery Disease.
Topics: Animals; Anticholesteremic Agents; Autoimmunity; Biomarkers; Coronary Artery Disease; Dyslipidemias; Ezetimibe; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Periodicals as Topic; Phenotype; Risk Factors | 2020 |
Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials.
Topics: Cholesterol, LDL; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dicarboxylic Acids; Drug Development; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Inflammation | 2021 |
Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients.
Topics: Asian People; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
Combination therapy in dyslipidemia: where are we now?
Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Niacin; Patient Compliance; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Treatment Outcome | 2014 |
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Risk Reduction Behavior; Thrombophilia | 2016 |
Pleiotropic effects of ezetimibe: do they really exist?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Disease Models, Animal; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Inflammation Mediators; Lipid Metabolism; Platelet Aggregation; Treatment Outcome | 2010 |
Aortic stenosis and lipids: does intervention work?
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Biomarkers, Pharmacological; Calcinosis; Disease Progression; Endothelium, Vascular; Ezetimibe; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Simvastatin; Stress, Physiological | 2010 |
Statins for calcific aortic valve stenosis: into oblivion after SALTIRE and SEAS? An extensive review from bench to bedside.
Topics: Animals; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Azetidines; Calcinosis; Disease Progression; Endothelium, Vascular; Ezetimibe; Heart Valve Prosthesis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oxidative Stress; Randomized Controlled Trials as Topic | 2010 |
[New results in the management of hypercholesterolemia].
Topics: Anticholesteremic Agents; Azetidines; C-Reactive Protein; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Enzyme Inhibitors; Evidence-Based Medicine; Ezetimibe; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Practice Guidelines as Topic; Sterol O-Acyltransferase | 2005 |
9 trial(s) available for ezetimibe and Inflammation
| Article | Year |
|---|---|
Effects of rosuvastatin/ezetimibe on senescence of CD8+ T-cell in type 2 diabetic patients with hypercholesterolemia: A study protocol.
Topics: CD8-Positive T-Lymphocytes; Cholesterol, LDL; Cytokines; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Randomized Controlled Trials as Topic; Rosuvastatin Calcium | 2022 |
Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers.
Topics: Aged; Asian People; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged | 2018 |
Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Desmosterol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phytosterols; Prospective Studies; Pyrroles; Risk Factors; Sitosterols; Statistics, Nonparametric | 2013 |
Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Case-Control Studies; Chemokine CCL2; Cross-Over Studies; Diabetes Mellitus; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Inflammation; Inflammation Mediators; Interferon-gamma; Male; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2014 |
Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
Topics: Aged; Allantoin; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Healthy Volunteers; Humans; Inflammation; Kynurenine; Male; Malondialdehyde; Middle Aged; NF-kappa B; Oxidative Stress; Renal Insufficiency, Chronic; Simvastatin; Taurine; Triglycerides; Tryptophan; Uric Acid | 2015 |
The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels.
Topics: Anticholesteremic Agents; Azetidines; Cytokines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Inflammation; Lymphocytes; Male; Middle Aged; Prospective Studies; Simvastatin | 2012 |
Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Serum Amyloid P-Component; Sulfonamides; Tumor Necrosis Factor-alpha | 2013 |
The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
Topics: Administration, Oral; Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; C-Reactive Protein; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2007 |
Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis.
Topics: Aged; Anticholesteremic Agents; Aorta; Arthritis, Rheumatoid; Azetidines; Blood Flow Velocity; C-Reactive Protein; Cholesterol; Cross-Over Studies; Double-Blind Method; Elasticity; Endothelium, Vascular; Ezetimibe; Female; Humans; Inflammation; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Stress, Mechanical | 2007 |
27 other study(ies) available for ezetimibe and Inflammation
| Article | Year |
|---|---|
Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response.
Topics: Animals; Anticholesteremic Agents; Cell Proliferation; Cholesterol; Dose-Response Relationship, Drug; Foam Cells; HEK293 Cells; Humans; Inflammation; Lipids; Macrophages; Mice; Molecular Structure; Pyrroles; RAW 264.7 Cells; Structure-Activity Relationship | 2018 |
Ezetimibe Prevents IL-1β-induced Inflammatory Reaction in Mouse Chondrocytes
Topics: Aggrecans; Animals; Anti-Inflammatory Agents; Cells, Cultured; Cholesterol; Chondrocytes; Ezetimibe; Inflammation; Interleukin-1beta; Matrix Metalloproteinase 13; Matrix Metalloproteinase 3; Mice; NF-E2-Related Factor 2; NF-kappa B; Osteoarthritis | 2022 |
Ezetimibe attenuates functional impairment via inhibition of oxidative stress and inflammation in traumatic spinal cord injury.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Ezetimibe; Inflammation; Male; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Oxidative Stress; Spinal Cord Injuries | 2023 |
[Pleiotropic effects of ezetimibe].
Topics: Anticholesteremic Agents; Ezetimibe; Humans; Inflammation; Plaque, Atherosclerotic | 2019 |
Ezetimibe Attenuates Oxidative Stress and Neuroinflammation via the AMPK/Nrf2/TXNIP Pathway after MCAO in Rats.
Topics: AMP-Activated Protein Kinases; Animals; Cell Cycle Proteins; Disease Models, Animal; Ezetimibe; Infarction, Middle Cerebral Artery; Inflammation; Male; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2020 |
Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia.
Topics: Animals; Aspirin; Chemoprevention; Cholecystolithiasis; Cholesterol; Cholesterol, Dietary; Chronic Disease; Diet; Disease Models, Animal; Disease Progression; Ezetimibe; Fatty Liver; Feeding Behavior; Gallbladder Neoplasms; Gallstones; Inflammation; Male; Metaplasia; Mice, Inbred C57BL; Precancerous Conditions; Spleen | 2020 |
Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Autophagy-Related Protein 7; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cells, Cultured; Down-Regulation; Ezetimibe; Fatty Liver; Female; Hep G2 Cells; Humans; Inflammasomes; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction | 2017 |
Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.
Topics: Adipokines; Adult; Aged; Anticholesteremic Agents; Biomarkers; Blood Glucose; Cytokines; Diabetes Mellitus; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Monocytes; RNA, Messenger; Simvastatin | 2017 |
Ezetimibe prevents myocardial remodeling in an obese rat model by inhibiting inflammation.
Topics: Animals; Anticholesteremic Agents; Blotting, Western; C-Reactive Protein; Cardiomegaly; Collagen; Diet, High-Fat; Ezetimibe; Heart; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Myocardium; Obesity; p38 Mitogen-Activated Protein Kinases; Rats, Sprague-Dawley; Vascular Cell Adhesion Molecule-1; Ventricular Remodeling | 2018 |
Simvastatin and Simvastatin-Ezetimibe Improve the Neurological Function and Attenuate the Endothelial Inflammatory Response after Spinal Cord Injury in Rat.
Topics: Animals; Anticholesteremic Agents; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Inflammation; Male; Motor Activity; Neurons; Rats; Rats, Sprague-Dawley; Recovery of Function; Simvastatin; Spinal Cord Injuries | 2019 |
Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort.
Topics: Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cross-Sectional Studies; Ezetimibe; Female; Humans; Incidence; Inflammation; Male; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies | 2020 |
Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy.
Topics: Aged; Amygdala; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Azetidines; Brain; Cognition; Electrocardiography; Executive Function; Ezetimibe; Female; Heptanoic Acids; Hippocampus; Humans; Image Processing, Computer-Assisted; Inflammation; Magnetic Resonance Imaging; Male; Memory; Neuroimaging; Neuropsychological Tests; Psychomotor Performance; Pyrroles; Reaction Time; Vocabulary | 2013 |
Effects of simvastatin, ezetimibe, and their combination on histopathologic alterations caused by adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Arthritis; Azetidines; Cartilage, Articular; Disease Progression; Drug Therapy, Combination; Ezetimibe; Flow Cytometry; Freund's Adjuvant; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Rats; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment.
Topics: Adult; Aged; Anthropometry; Anticholesteremic Agents; Azetidines; Biomarkers; Cells, Cultured; Cholesterol, LDL; Culture Media; Drug Therapy, Combination; Ezetimibe; Female; Gene Expression Profiling; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation; Leukocytes, Mononuclear; Male; Middle Aged; Phenotype; Serum; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins; Tumor Necrosis Factor-alpha | 2014 |
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Female; Humans; Inflammation; Kynurenine; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Renal Insufficiency, Chronic; Simvastatin; Uric Acid | 2016 |
Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Cell Adhesion; Cytokines; Drug Therapy, Combination; Ezetimibe; Inflammation; Knee Joint; Leukocyte Rolling; Leukocytes; Rats; Simvastatin | 2017 |
Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Line; Cell Movement; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Male; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
Ezetimibe - new anti-atherogenic properties?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Movement; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Topics: Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Fatty Liver; Humans; Inflammation; Insulin Resistance; Liver; Membrane Proteins; Membrane Transport Proteins | 2010 |
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex | 2010 |
Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia.
Topics: Administration, Oral; Anticholesteremic Agents; Asian People; Atherosclerosis; Azetidines; Biomarkers; Case-Control Studies; Ezetimibe; Female; Humans; Hypercholesterolemia; Inflammation; Insulin Resistance; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Liver Diseases; Male; Matrix Metalloproteinase 9; Middle Aged; Prognosis; Prospective Studies; Vascular Cell Adhesion Molecule-1 | 2012 |
Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Dose-Response Relationship, Drug; Ezetimibe; Female; Follow-Up Studies; Humans; Hyperlipidemias; Inflammation; Lipids; Male; Treatment Outcome | 2013 |
Ezetimibe ameliorates early diabetic nephropathy in db/db mice.
Topics: Adiponectin; Adiposity; Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blotting, Western; Body Weight; Creatinine; Diabetic Nephropathies; Ezetimibe; Glomerular Filtration Rate; Inflammation; Kidney Function Tests; Lipid Metabolism; Male; Metabolism, Inborn Errors; Mice; Mice, Obese; Obesity; Oxidative Stress; Real-Time Polymerase Chain Reaction; Receptors, Adiponectin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2012 |
Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model.
Topics: Animals; Anticholesteremic Agents; Azetidines; Disease Models, Animal; Ezetimibe; Fatty Acids; Fatty Liver; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Oryzias | 2012 |
Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammation.
Topics: Adipose Tissue; Animals; Atherosclerosis; Azetidines; Cholesterol; Ezetimibe; Immunohistochemistry; Inflammation; Insulin Resistance; Intestinal Absorption; Intestines; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Real-Time Polymerase Chain Reaction; Receptors, LDL; Weight Gain | 2012 |
After ENHANCE: is more LDL cholesterol lowering even better?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Carotid Artery Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation; Lipid Metabolism; Simvastatin | 2008 |
Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Arteriosclerosis; Azetidines; Blood Pressure; Endothelium, Vascular; Ezetimibe; Female; Hypercholesterolemia; Inflammation; Lipids; Male; Mice; Mice, Knockout; Nitric Oxide Synthase Type III | 2009 |